knowledge -WSS

knowledge

author：comprehensive 2025-09-27 09:40:32 - browse：6

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Goldman Sachs launches $650M fund for life science investments

WSS

Researchers use wearables data and AI to predict preterm birth risk

Medicaid, Medicare dual

Morgan Health, with ambitious aims, wants you to know it’s still here

Address the ethical violations that led to 'Three Identical Strangers'

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Medicaid, Medicare dual

knowledge

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

New air purifier tech could be key to improving indoor air quality

White House finalizes ITC's import ban of latest Apple Watches

Medicare details structure of new drug price negotiation program

The biotech scorecard for Q1: 17 stock

Hepatitis C has a cure — but many Americans still lack access to it

Goldman Sachs launches $650M fund for life science investments

Apple is now the first public company to be valued at $3 trillion

Feng Zhang, Grail founder join forces on new gene editing startup

Jerome Adams on the need for new antivirals for Covid

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

focus

Covid vaccines: Private market messier than government rollout

3 medical device trends to watch in 2024

UCB departs biotech trade group BIO

New weight loss drugs work. But how can they best be used?

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Senator probes 340B programs at Cleveland Clinic, Bon Secours

hotspot

Wikipedia

knowledge

Wikipedia